READ THE FULL ARTICLEis the only listed company on the ASX which is tackling this side effect problem head-on.
Recent animal study has shown that Noxopharm’s SOF-VAC mRNA vaccine enhancer significantly reduces mRNA-driven inflammation by as high as 50%.
“This enhancer works on specific cell receptors in the body to block inflammation at its source,” CEO of Noxopharm, Dr Gisela Mautner, told *.
mRNA is the next big thing in medicine. Here’s why Noxopharm could be the ASX front runner in this field
Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction, page-24
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $23.08M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.6¢ | $11.76K | 150.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 119201 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.0¢ | 21000 | 2 |
View Market Depth
| Last trade - 15.56pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
-0.001 ( 1.27 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.8¢ | 72652 | ||
| Last updated 11.12am 03/06/2024 ? | |||||
| NOX (ASX) Chart |